Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

References

• American Diabetes Association. Standards of medical care in diabetes – 2015. Diabetes Care 2015;38(Supp 1):S1-93
   Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet, 2014. Available at: http://www.cdc.gov//diabetes/pubs/statsreport14/national-diabetes-report-web.pdf [Last accessed 1 May 2015]
   Google Scholar
• Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2015;38:1364-9
   Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract 2015;21:438–47
   PubMed Web of Science ®Google Scholar
• Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27:136-42
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
   PubMed Web of Science ®Google Scholar
• Invokana (canagliflozin) tablets [product information]. Titusville, NJ: Janssen Pharmaceuticals Inc., March 2013
   Google Scholar
• Farxiga (dapagliflozin) tablets [product information]. Princeton, NJ: Bristol-Myers Squibb, January 2014
   Google Scholar
• Jardiance (empagliflozin) tablets [product information]. Ridgefield, CT: Boehringer Ingelheim, April 2014
   Google Scholar
• Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2014;16:984-63
   PubMed Web of Science ®Google Scholar
• Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs 2014;74:611-17
   PubMed Web of Science ®Google Scholar
• Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs 2014;74:939-44
   PubMed Web of Science ®Google Scholar
• Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 2013;139:51-9
   PubMed Web of Science ®Google Scholar
• Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs 2014;74:945-50
   PubMed Web of Science ®Google Scholar
• Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014;30:1245-55
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92:158-69
   PubMed Web of Science ®Google Scholar
• Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:313-27
   PubMedGoogle Scholar
• Angelopoulos TP, Doupis J. Sodium-glucose linked transporter 2 (SGLT2) inhibitors – fighting diabetes from a new perspective. Adv Ther 2014;31:579-91
   PubMed Web of Science ®Google Scholar
• Cangoz S, Chang YY, Chempakaseril SJ, et al. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther 2013;38:350-9
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inbhitors for type 2 diabetes. Ann Intern Med 2013;159:262-74
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Pahor A, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med 2012;156:405-15
   PubMed Web of Science ®Google Scholar
• Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262-75
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-15
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomized, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Carious B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
   PubMed Web of Science ®Google Scholar
• Medication Guide Invokana (canagliflozin) tablets. Janssen. March 2013. Available at: http://www.invokanahcp.com/medication-guide.pdf [Last accessed 1 May 2015]
   Google Scholar
• Medication Guide Farxiga (dapagliflozin) tablets. Bristol-Myers Squibb. January 2014. Available at: http://www1.astrazeneca-us.com/pi/medguide_farxiga.pdf#page=1 [Last accessed 1 May 2015]
   Google Scholar
• FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 15 May 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm [Last accessed 24 June 2015]
   Google Scholar
• Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004;286:F8-15
   PubMed Web of Science ®Google Scholar
• Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol 2011;1:1175-232
   PubMed Web of Science ®Google Scholar
• Kanwar YS, Sun L, Xie P, et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011;6:395-423
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-3
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-14
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011;305:2184-92
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9
   PubMed Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
   PubMed Web of Science ®Google Scholar
• George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabetic Med 2013;30:179-88
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care 2012;35:2198-200
   PubMed Web of Science ®Google Scholar
• Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-19
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics Inc. Micromedex Clinical Evidence Solutions. Truven Health Analytics Inc, Greenwood Village, CO. Red Book Drug References, c2014 [Last accessed 24 November 2014]
   Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013;41:72-84
   PubMedGoogle Scholar
• Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45
   PubMed Web of Science ®Google Scholar
• Nicolle L, Usiskin K, Capuano G, et al. No increase in bacteriuria or urinary tract infections in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin, a sodium glucose co-transporter (SGLT2) inhibitor (abstract 43-LB). Diabetes 2011;60(Suppl 1A):LB12
   Google Scholar
• Leiter La, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64
   PubMed Web of Science ®Google Scholar